|
Jul 23
|
Ensysce Biosciences Provides Mid-Year 2024 Update
|
|
Apr 25
|
Ensysce Biosciences’ CEO Dr. Lynn Kirkpatrick Featured in Xtalks Clinical Edge Magazine
|
|
Dec 19
|
Ensysce Biosciences Postpones Special Meeting of Stockholders to December 29, 2023
|
|
Dec 14
|
Ensysce Biosciences Announces Key Efficacy Data for Lead Analgesic
|
|
Dec 11
|
Ensysce Biosciences Discusses TAAP and MPAR(R) Applications and OncoZenge Partnership with The Stock Day Podcast
|
|
Nov 29
|
Ensysce Biosciences Announces Completion of $1.7 Million Convertible Note Financing
|
|
Nov 28
|
Ensysce Biosciences and OncoZenge Announce Letter of Intent for the Co-development of BupiZenge(TM) in the United States
|
|
Oct 18
|
Ensysce Biosciences Announces Poster Presentation at the AAPS 2023 PharmSci 360
|
|
Jun 27
|
Ensysce Biosciences and Quotient Sciences to Present MPAR(R) Overdose Protection Platform at Upcoming CRS 2023 Annual Meeting and Expo
|
|
Mar 22
|
Ensysce Biosciences Announces Completion of Enrollment for Groundbreaking Opioid Overdose Protection Study
|